Quick recap
Growth strategy focused on China's infant milk formula market
Full-year results show double-digit revenue and earnings growth
China sales up 38%, record market share in China label IMFMarketing investment up 13% to $260m boosts
China brand healthTotal IMF sales rise 8% despite market decline of 14%
China IMF market decline due to fewer newborns and increased competition
Revenue grows 10.1% to $1,592.9 million with varied regional sales
EBITDA up 11.8% to $219.3 million
NPAT up 26.2% to $144.8 million
Earnings per share rise 28.7% to 21.2 cents
Company expects growth in FY24 despite market challenges.
Ann: FY23 Annual Report, page-4
-
- There are more pages in this discussion • 109 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.68 |
Change
-0.020(0.30%) |
Mkt cap ! $4.829B | |||
| Open | High | Low | Value | Volume |
| $6.70 | $6.71 | $6.61 | $6.477M | 971.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12782 | $6.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.69 | 15324 | 5 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| A2M (ASX) Chart |